Inactive Instrument
Antibe Therapeutics Inc. Share Price
Stocks
ATE
CA0370255097
Biotechnology & Medical Research
OTC Markets Traded| 04/07/24 | Antibe Therapeutics : NOTICE TO CLAIMANTS OF ANTIBE THERAPEUTICS INC. (“ANTIBE”) | PU |
| 24/04/24 | Antibe Announces Appointment of Receiver | BU |
| 22/04/24 | ANTIBE PROVIDES UPDATE ON CCAA PROCEEDINGS | AQ |
| 19/04/24 | Antibe Provides Update on CCAA Proceedings | BU |
| 16/04/24 | Antibe Announces TSX Delisting Review | BU |
| Manager | Title | Age | Since |
|---|---|---|---|
Alain Wilson
DFI | Director of Finance/CFO | - | 30/11/2015 |
David Vaughan
CTO | Chief Tech/Sci/R&D Officer | 76 | - |
| Investor Relations Contact | 50 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 08/03/24 | Option | Chief Technology Officer | 16,666 | 0.0317% | ||
| 08/03/24 | Option | Chief Technology Officer | 9,000 | 0.0171% | ||
| 08/03/24 | Option | Chief Executive Officer | 35,000 | 0.0665% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +59.46% | - | - | 11.47M | |
| +8.49% | +23.38% | +65.44% | +104.90% | 62.92B | |
| +1.25% | +2.44% | +32.55% | +72.63% | 54.32B | |
| +2.11% | +2.70% | -16.45% | -5.55% | 22.91B | |
| -1.36% | +32.05% | +19.12% | +495.34% | 28.73B | |
| +10.83% | +21.32% | +45.03% | +2.02% | 21.65B | |
| +6.50% | +7.56% | +38.20% | -21.33% | 17.76B | |
| -3.88% | +20.98% | +201.07% | +350.94% | 16.47B | |
| +6.20% | +12.16% | +28.51% | +629.05% | 15.48B | |
| +2.67% | +1.64% | +44.16% | +166.17% | 13.12B | |
| Average | +3.28% | +7.42% | +50.85% | +199.35% | 28.15B | |
| Weighted average by Cap. | +4.05% | +9.95% | +47.54% | +165.82% |
Employees
11
